Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Mar 27, 2023; 15(3): 377-385
Published online Mar 27, 2023. doi: 10.4254/wjh.v15.i3.377
Challenges and recommendations when selecting empirical antibiotics in patients with cirrhosis
Melisa Dirchwolf, Gonzalo Gomez Perdiguero, Ingrid Mc Grech, Sebastian Marciano
Melisa Dirchwolf, Ingrid Mc Grech, Liver Unit, Hospital Privado de Rosario, Rosario 2000, Santa Fe, Argentina
Gonzalo Gomez Perdiguero, Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires 1181, Argentina
Sebastian Marciano, Liver Unit and Department of Research, Hospital Italiano de Buenos Aires, Buenos Aires 1181, Argentina
Author contributions: All authors performed the literature research, wrote and revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sebastian Marciano, MD, MSc, Academic Research, Associate Research Scientist, Chief Doctor, Liver Unit and Department of Research, Hospital Italiano de Buenos Aires, Juan Domingo Perón 4190, Buenos Aires 1181, Argentina. sebastian.marciano@hospitalitaliano.org.ar
Received: November 12, 2022
Peer-review started: November 12, 2022
First decision: November 23, 2022
Revised: December 28, 2022
Accepted: March 10, 2023
Article in press: March 10, 2023
Published online: March 27, 2023
Processing time: 130 Days and 10.7 Hours
Abstract

There is abundant evidence that bacterial infections are severe complications in patients with cirrhosis, being the most frequent trigger of acute-on-chronic liver failure and causing death in one of every four patients during hospitalization. For these reasons, early diagnosis and effective treatment of infections are mandatory to improve patient outcomes. However, treating physicians are challenged in daily practice since diagnosing bacterial infections is not always straightforward. This situation might lead to delayed antibiotic initiation or prescription of ineffective regimens, which are associated with poor outcomes. On the other hand, prescribing broad-spectrum antibiotics to all patients suspected of bacterial infections might favor bacterial resistance development. This is a significant concern given the alarming number of infections caused by multidrug-resistant microorganisms worldwide. Therefore, it is paramount to know the local epidemiology to propose tailored guidelines for empirical antibiotic selection in patients with cirrhosis in whom bacterial infections are suspected or confirmed. In this article, we will revise current knowledge in this area and highlight the importance of surveillance programs.

Keywords: Bacterial infections; Cirrhosis; Multidrug resistance; Antibiotic prophylaxis; Antibiotic stewardship

Core Tip: Practitioners who participate in caring for patients with cirrhosis are challenged when using antibiotics rationally. On one side, bacterial infections are frequent, severe, and not always straightforward to diagnose; on the other, scant granular data is publicly available about the causal microorganisms and their susceptibility patterns. According to experts, empiric antibiotic treatments should cover 80% of the common pathogens in stable patients and 90% in critically ill patients with suspected infections. Therefore, it is necessary to know the microorganisms expected to be involved in the most frequent bacterial infections and their susceptibility patterns to develop evidence-based guidelines. This opens a window of opportunity for research because bacterial infections and multidrug resistance are global health issues expected to grow over the following decades.